# Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

> **NCT00088192** · NA · COMPLETED · sponsor: **Eyetech Pharmaceuticals**

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** pegaptanib sodium

## Key facts

- **NCT ID:** NCT00088192
- **Lead sponsor:** Eyetech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088192, "Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00088192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*